**Glossary**

EPSPS:5-enolpyruvylshikimate-3-phosphate synthase PAT:Phosphinothricin-N-acetyltransferase ALS:Acetolactate synthase DMO: Dicambamonooxygenase HPPD:Hydroxyphenylpyruvatedioxygenase GM:Genetically modified Bt:*Bacillus thuringiensis* Cry1:Crystalline proteins QTL:Quantitative trait loci BPMV:Bean pod mottle virus SMV:Soybean mosaic virus SbDV:Soybean dwarf virus

SSR*:Sclerotinia* stem rot

OA:Oxalic acid

ambient storage conditions. They have been engineered to express a variety of potential therapeutics, including mAbs, vaccine antigens and adjuvants, hormones, growth factors, and blood-clotting factors. Seed-based expression of 660 kDa homodimerich TG underscores the potential of the soybean system to produce large and complex proteins that cannot be produced in yeast, insect, and mammalian cell cultures. The efficacy of engineered thera‐ peutics in crude soymilk formulations could lead to oral vaccines and therapies that require little, if any, purification from other seed proteins. Reports demonstrating long-term stabili‐ ty of seed-derived therapeutics in the absence of climate control directly address cold chain issues associated with vaccines and other therapeutics. With seed protein levels of ~40% and transgene expression levels approaching 3% of TSP, a single soybean plant yielding 300 seeds can produce >500 mgs of transgenic protein. To put this in perspective, a single soy‐ bean plant can produce 500 doses of a vaccine antigen administered at 1 mg/ml, or alterna‐

A Comprehensive Survey of International Soybean Research - Genetics, Physiology, Agronomy and Nitrogen

The use of soybean as a platform for the production of therapeutics represents a technology with the potential to revolutionize our current approaches to healthcare. Harnessing the full potential of the soybean platform will depend on further increasing stable transgene expres‐ sion levels, developing efficient purification methods, obtaining interest from pharmaceuti‐ cal partners, and overcoming issues associated with commercialization. The production of vaccines, antibodies, and other therapeutic proteins will undoubtedly continue to develop over the next decade. As biotechnology evolves, so does the role of soybean - from the field

tively, \$50,000 [USD] of a therapeutic valued at \$100/mg [USD].

EPSPS:5-enolpyruvylshikimate-3-phosphate synthase

PAT:Phosphinothricin-N-acetyltransferase

HPPD:Hydroxyphenylpyruvatedioxygenase

ALS:Acetolactate synthase

GM:Genetically modified

Cry1:Crystalline proteins

QTL:Quantitative trait loci

BPMV:Bean pod mottle virus

SMV:Soybean mosaic virus

SbDV:Soybean dwarf virus

Bt:*Bacillus thuringiensis*

DMO: Dicambamonooxygenase

to the bedside.

Relationships

466

**Glossary**

OXDC:Oxalate decarboxylase

CHI:Chitinase

RIP:Ribosome-inactivating protein

scFv:Single-chain variable fragment

SDS:Sudden death syndrome

RKN:Root knot nematodes

SCN:Soybean cyst nematodes

RNAi:RNA interference

MSP:Major sperm protein

TP:Tyrosine phosphatase

TAGs:Triacylglycerols

DAGS:Diacylglycerols

SCL1:Yeast sphingolipid compensation protein

LPAT:Lysophosphatidic acid acyltransferase

LA:Linolenic acid

OA:Oleic acid

GLA:γ-linolenic acid

SDA:Stearidonic acid

ALA:α-linolenic

EPA:Eicosapentaenoic acid

DHA:Docosahexaenoic acid

HPT:Homogentisatephytyltransferase

HGGT:Homogentisategeranylgeranlytransferase

OASS:O-acetylserinesulfhydrylase

TSP:Total soluble protein

PSV:Protein storage vacuole

mAbs:Monoclonal antibodies (mAbs)

HSV-2:Herpes simplex virus 2

	- LT:Heat labile toxin of *E*. *coli* ETEC:Enterotoxigenic*E*. *coli* PRRS:Porcine reproductive and respiratory syndrome hGH:Human growth hormone bFGF:Human basic fibroblast growth factor hFIX:Human coagulation factor IX hTG:Human thyroglobulin GFP:Green Fluorescent Protein
